Molecular International Prognostic Scoring System Developed for Myelodysplastic Syndromes
12 juin 2022 10h00 HE
|
MDS Foundation, Inc. (963786)
YARDVILLE, N.J., June 12, 2022 (GLOBE NEWSWIRE) -- Today, the MDS Foundation announced the development of a new prognostic scoring system, the IPSS-Molecular, that will significantly improve risk...
The MDS Foundation Celebrates MDS World Awareness Day With Their 4th Annual Move for MDS 5k Walk at Boston Common and Virtually Around the World
20 oct. 2021 10h05 HE
|
MDS Foundation, Inc.
YARDVILLE, N.J., Oct. 20, 2021 (GLOBE NEWSWIRE) -- The MDS Foundation, a global non-profit advocacy organization is proud to announce its fourth annual Move for MDS walk at Boston Common on Sunday,...
Geron Corporation Reports Third Quarter 2020 Financial Results and Current Events
05 nov. 2020 16h05 HE
|
Geron Corporation
FOSTER CITY, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today reported financial results for the third quarter ended...
Geron Receives Positive Opinion from the EMA Committee for Orphan Medicinal Products for Orphan Drug Designation in the European Union for Imetelstat to Treat Myelodysplastic Syndromes
01 juil. 2020 08h30 HE
|
Geron Corporation
Designation would provide 10-year period of marketing exclusivity in the European Union after product approvalPatients are currently enrolling in a Geron-sponsored Phase 3 clinical trial in lower risk...
Geron Reports Four Imetelstat Data Presentations at Virtual Edition of the European Hematology Association (EHA) Annual Congress
12 juin 2020 08h30 HE
|
Geron Corporation
For the IMerge Phase 2 clinical trial, meaningful and durable transfusion independence reported with a new 1-year TI rate, indicating potential disease-modifying activity of imetelstat treatmentFor...
Geron Corporation Reports First Quarter 2020 Financial Results
28 mai 2020 16h05 HE
|
Geron Corporation
MENLO PARK, Calif., May 28, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today reported financial results for the first quarter ended March 31, 2020. The Company will host a conference...
Geron Corporation Announces the Closing of its Public Offering of Common Stock and Warrants
27 mai 2020 16h30 HE
|
Geron Corporation
MENLO PARK, Calif., May 27, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the closing of its previously announced...
Geron Corporation Announces the Pricing of its Public Offering of Common Stock and Warrants
22 mai 2020 07h15 HE
|
Geron Corporation
MENLO PARK, Calif., May 22, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the pricing of its previously announced...
Geron Corporation Announces Proposed Public Offering of Common Stock and Warrants
21 mai 2020 16h03 HE
|
Geron Corporation
MENLO PARK, Calif., May 21, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it intends to offer and sell shares of...
Geron Announces Plans for Imetelstat Phase 3 Clinical Trial in Myelofibrosis and Other Updates
21 mai 2020 16h01 HE
|
Geron Corporation
Geron plans to move forward with a Phase 3 clinical trial in refractory myelofibrosis (MF) with overall survival (OS) as a primary endpoint, which is expected to open for screening and enrollment in...